Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC - Episode 8
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
Related Content: